Azole resistance in Aspergillus fumigatus is predominantly associated with increased expression 24 of Cyp51A (lanosterol 14α-demethylase), the target enzyme of azole antifungal agents, or with 25 single-nucleotide polymorphisms (SNPs) in cyp51A. Although several SNPs that may be linked 26 to low susceptibility in azole-resistant isolates have previously been reported, few studies have 27 been conducted to conclusively demonstrate the contribution of SNPs to decreased azole 28
Introduction 46
The filamentous fungi Aspergillus fumigatus is the most common opportunistic human fungal 47 pathogen, with a wide range of clinical features including invasive pulmonary aspergillosis, 48 chronic progressive pulmonary aspergillosis (CPPA), and allergic bronchopulmonary 49 aspergillosis (1). Triazole antifungal drugs are the most common treatment for A. fumigatus 50 infection. Itraconazole (ITC) and voriconazole (VRC) are the only oral drug treatment options 51 for aspergillosis, which may lead to long-term administration. Since the discovery of the first 52 ITC-resistant isolate in 1997 (2) The primary molecular mechanisms of triazole resistance in A. fumigatus isolates are mutations 58 that alter the target protein Cyp51A and prevent its interaction with the drug (4). Mutations in 59 cyp51A may be classified as single-nucleotide polymorphisms (SNPs) and/or tandem repeats in 60 the promoter region (3). The major SNPs affecting Cyp51A are positioned at Gly54, Gly138, 61 Met220, and Gly448. The clinical isolates having these SNPs demonstrate various azole 62 susceptibility profiles; for example, isolates with SNPs at Gly54 show resistance to ITC and 63 varied susceptibility to posaconazole (POS) and VRC, whereas isolates with SNPs at Gly138 64 show resistance to pan-azoles, including ITC, POS, and VRC. Another alteration is a tandem 65 repeat in the promoter region that results in the overexpression of cyp51A. Two major classes of 66 such azole-resistant mutants are TR34/Leu98His and TR46/Tyr121Phe/Thr289Ala, which carry a 67 34-bp and a 46-bp sequence duplication, respectively, as well as amino acid substitutions. 68 4 Although many SNPs in cyp51A that may be linked to low susceptibility in azole-resistant 69 isolates have been previously reported, few studies have been conducted to conclusively 70 demonstrate the contribution of SNPs to decreased azole susceptibility in clinical isolates. One 71 obstacle affecting the molecular analysis of clinical A. fumigatus isolates is the production of 72 genetically manipulated mutants, as the efficiency of homologous recombination is extremely 73 low. 74 75 Cas9/CRISPR (the clustered regularly interspaced short palindromic repeats) is essentially a 76 bacterial defense system for adaptive immunity against invading nucleic acids and has been 77 applied as a powerful genome editing tool in various organisms (5). By forming a 78 ribonucleoprotein complex with an artificial single-guide RNAs (sgRNAs) designed to target a 79 cellular gene, the Cas9 nuclease efficiently introduces double-stranded breaks (DSBs) at the 80 corresponding target locus (6). The sgRNA hybridizes to its complementary DNA sequence, 81 immediately upstream of the protospacer adjacent motif (PAM), which consists of NGG for the 82 Streptococcus pyrogenes Cas9 variant (7) . DSBs in the target genomic DNA can be repaired 83 either by homology-directed repair or non-homologous end joining (NHEJ) (5, 8, 9) . DNA repair 84 via homology-directed repair requires a homologous DNA template with sequence similarity to 85 the adjacent region of the DSB locus, whereas NHEJ ligates the DSB, leading to indels in a 86 template-independent manner. The Cas9/CRISPR system has also been successfully applied to 87 A. fumigatus (10) (11) (12) . 88
89
In the present study, we investigated the antifungal mechanisms of a pan-azole-resistant strain 90 isolated from a patient receiving long-term VRC treatment for CPPA. Although two 91 5 polymorphisms were found in cyp51A from the isolate, it was unclear which of the SNPs 92 contributed to low azole susceptibility. We genetically demonstrated that one of the SNPs 93 predominantly contributes to low susceptibility in the azole-resistant clinical isolate using a 94 sgRNA in vitro synthesis. We manually searched for target sequences consisting of 117 G(N)15(A/T)(N)3NGG near the N-terminus (for sgRNA1) and C-terminus (for sgRNA2) as 7 sgRNA target sequences and synthesized two oligonucleotides (T7-sgRNA1 and T7-sgRNA2, 119 Table 3 . Briefly, NIID0345 or AfS35 genomic DNA was used as a template to 135 generate overlapping PCR products with the corresponding site-specific mutations or junctions 136 between cyp51A and the hph marker. The overlapping PCR products were mixed together and 137 used as a template in the PCR-sewing step using the primers LFH1 and LFH4. Overlapping PCR 138 product combinations are listed in Table 4 . The fused PCR products were purified using a 139 NucleoSpin® Gel and PCR Clean-up kit (Takarabio, Japan) and used for A. fumigatus protoplast 140 transformation. 141 8 142 A. fumigatus transformation. A. fumigatus protoplasts were generated and fungal 143 transformation was performed as previously described (13), with slight modifications. Briefly, 144 conidia were incubated in YG medium for 6 h at 37°C. Following incubation, the cell walls of 145 germlings were digested with 0.2 g/mL VinoTaste Pro (Novozymes, Denmark) for 1 h at 30°C; 146 20 pmol Cas9-NLS protein (New England Biolabs) and 10 pmol each in vitro-synthesized 147 sgRNA1 and sgRNA2 were mixed and incubated for 25 min, generating ribonucleoproteins 148 (RNPs). Protoplasts were transformed with 2-3 µg of repair templates and RNPs and plated onto 149 CD supplemented with 1 M sucrose. Using NIID0345 clinical isolate as a host, repair templates 150 0345-mut1-S138-K248-mut2-hph, 0345-mut1-G138-K248-mut2-hph, 151 0345-mut1-S138-N248-mut2-hph, or 0345-mut1-G138-N248-mut2-hph were used to generate 152 strains NIID0345-mut1-2, NIID0345-S138G, NIID0345-K248N, or NIID0345-S138G-K248N, 153
respectively. Using AfS35 strain as a host, repair templates 35-mut1-G138-mut2-hph or 154 35-mut1-S138-mut2-hph were used to generate strains AfS35-mut1-2 or AfS35-G138S, 155 respectively. Following a 15-h incubation at 37°C, plates were overlaid with CD top agar 156 containing 400 µg/mL hygromycin. Positive colonies were confirmed by colony PCR using 157 KOD FX Neo DNA polymerase (TOYOBO, Japan) with the primers Discheck5 and Discheck3 158 (which were designed at the region outside the repair template sequence), followed by nucleotide 159 sequencing of cyp51A, including the promoter region. 160 161 Antifungal susceptibility testing. Susceptibility to VRC, ITC, and POS were evaluated with 162
Etest strips according to the manufacturer's instruction (Biomerieux, France). Strains were 163 grown at 37°C, and growth inhibition was visually evaluated after 48 h. Susceptibility tests were 164
Results 166
Gly138Ser and Asn248Lys were found in the Cyp51A sequence of an azole-resistant clinical 167 isolate 168
The susceptibilities of the clinical isolate from a patient with CPPA were determined by Etest 169 methods. The isolate was not susceptible to VRC, ITC, or POS (Fig.1) , but was susceptible to 170 amphotericin B, micafungin, and caspofungin (data not shown). We identified NIID0345 as an A. 171 fumigatus strain via sequence analysis of the ITS and D1/D2 regions and the β-tubulin gene. 172
Comparison of cyp51A from the azole-resistant isolate (NIID0345) with those from 173 azole-susceptible strains (Af293 and AfS35) revealed that NIID0345 carried two amino acid 174 substitutions: Gly138Ser (GGC→AGC) and Asn248Lys (AAT→AAA). These results indicated 175 that one or both of these SNPs may be responsible for azole resistance. To verify which SNP is involved in azole resistance, we substituted the nucleotide sequences 179 corresponding to amino acid Ser138 and/or Lys248 in the clinical isolate NIID0345. We 180 attempted to replace the genomic cyp51A gene locus with a linear DNA fragment harboring 181 mutations by homologous recombination. It is well known that the rate of homologous 182 recombination is very low in a host strain having an NHEJ repair pathway, such as clinical 183
isolates. In addition, the Cas9/CRISPR system can be used to increase the efficiency of 184 homologous recombination in Candida glabrata (15). Therefore, we used Cas9/CRISPR to 185 create double-stranded breaks close to the N-and C-terminus of the cyp51A coding region, and 186 to facilitate the replacement of the genomic cyp51A locus with a repair template DNA fragment 187 via homologous recombination. Off-target effects are commonly encountered when Cas9 and 188 11 sgRNA are continuously expressed via the introduction of plasmid or DNA; however, recent 189 studies have shown that off-target effects were reduced by the direct introduction of the Cas9 190 protein and synthesized gRNA (16). Successful genome editing via the introduction of 191
Cas9-gRNA ribonucleoprotein has also been reported in filamentous fungi, such as A. fumigatus. 192 In the repair template DNA fragment, the nucleotide sequence responsible for amino acid 193 substitutions thought to confer azole resistance in NIID0345 was substituted for a nucleotide 194 sequence corresponding to that present in the azole-sensitive isolates. Furthermore, the construct 195 was made Cas9/CRISPR resistant by introducing nuclease-resistant silent mutations into the two 196 cyp51A gRNA target sites (Fig. 2) . Cas9/sgRNA ribonucleoproteins and the repair template were 197 simultaneously transformed via the protoplast-polyethylene glycol method into the A. fumigatus 198 azole-resistant clinical isolate, and the transformants were selected with hygromycin. By 199 confirming the nucleotide sequence of colony-directed PCR fragments of cyp51A, four kinds of 200 recombinant strains were produced: a strain with only the nuclease-resistant mutation, those with 201
Ser138Gly substitution, those with Lys248Asn substitution, and those with both Ser138Gly and 202 Lys248Asn substitutions. 203 204 Next, we examined azole susceptibility testing using Etest strips on the constructed recombinant 205 strains. The strains in which only nuclease-resistant silent mutations were introduced 206 demonstrated a similar azole-resistant profile as the parental strain NIID0345 (Fig. 3A) , 207
indicating that Cas9/CRISPR-mediated homologous recombination had no effect on azole 208 susceptibility. Both of the recombinant strains with Ser138Gly and Ser138Gly/Lys248Asn amino 209 acid substitutions showed increased susceptibilities to all azoles tested, whereas the strain with 210 only Lys248Asn substitution showed a similar azole-resistant profile to the parental clinical 12 isolate. These results indicate that Lys248 is not associated with azole resistance, and Ser138 is 212 responsible for azole resistance in this clinical isolate. 213
214
Gly 138 was substituted in the azole-susceptible strain AfS35. 215
To verify whether Gly138 in Cyp51A is responsible for azole resistance, amino acid substitution 216 of Gly138 to serine was introduced into the azole-susceptible strain AfS35. The method to 217 produce the recombinant strain was the same as above; however, highly efficient homologous 218 recombination was expected because the strain AfS35 is deficient in the NHEJ repair system. As 219 expected, almost all transformants exhibited ideal recombination. We constructed two kinds of 220 recombinant strains: a strain with only nuclease-resistant silent mutations and one in which 221
Gly138 was substituted with Ser138. Azole susceptibility testing by Etest of the recombinant 222 strains showed a slight decrease in azole susceptibility when the Ser138 mutation was introduced 223 into the azole-susceptible strain AfS35 (Fig. 3B ). The strain with only nuclease-resistant silent 224 mutations demonstrated a similar azole susceptibility profile as the parental strain AfS35. From 225 these results, we elucidated the direct involvement of Gly138 in Cyp51A in azole resistance, 226 which had previously been supported only by indirect epidemiological evidence. 227
Discussion 228
The Cas9/CRISPR genome editing technique used in this study has enabled site-directed 229 mutagenesis, altering Ser138 to glycine on the genomic Cyp51A locus in an azole-resistant 230 clinical strain. This is, to our knowledge, the first example of site-directed mutagenesis 231 performed in a clinical, azole-resistant fungal isolate to elucidate whether azole susceptibility is 232 altered by mutations in the genomic Cyp51A locus. Although many azole-resistant isolates with 233 SNPs in cyp51A have been identified, there have been few studies that genetically confirm their 234 correspondence to low azole susceptibility. Although genetically recombinant strains harboring 235 mutations such as TR34-Leu98His (17), TR46-Tyr121Phe-Thr289Ala (18), Gly54Trp (17), and 236
Thr301Ile (19) in the genomic Cyp51A locus have been reported to date, all these strains were 237 constructed in the akuB/Ku80-deficient strain as a recipient. It is well known that wild-type 238 strains, such as clinical isolates, tend to exhibit low efficiency in homologous recombination, 239 largely because of high NHEJ activity. To overcome this limitation, the gene encoding either 240 KU70 or Ku80, which are the components of NHEJ machinery, was knocked out, leading to a 241 significant increase in the frequency of homologous recombination (14, 20) . In contrast, our 242 method using Cas9/CRISPR can facilitate efficient homologous recombination without the 243 inactivation of the NHEJ pathway, which is supported by previous studies, concluding that the 244 frequency of homologous recombination can be increased by the Cas9/CRISPR system in C. 245 glabrata (15). 246
247
To build the Cas9/CRISPR system in A. fumigatus clinical isolates, we incorporated several 248 additional methods to improve the efficiency and accuracy of cyp51A gene replacement events. 249 Improved efficiency of cyp51A replacement was achieved by introducing two DSBs via the 250 14 design of two target sequences for sgRNA at sites close to the N-terminus and C-terminus, 251
repressing homologous recombination within the cyp51A coding region. Additionally, to avoid 252 digestion of the repair template and re-digestion of the edited target after the homologous 253 recombination event, nuclease-resistant silent mutations were introduced in two loci of three 254 codons immediately upstream from the PAM sites of the repair template, preventing it from 255 being targeted by Cas9/CRISPR(21). To minimize off-target effects from DNA-based continuous 256
Cas9 and sgRNA expression (which should be considered whenever Cas9/CRISPR system is 257 used for genome editing), we introduced ribonucleoproteins consisting of commercially available 258 recombinant Cas9 protein and in vitro-synthesized sgRNAs directly into protoplasts of clinical 259 isolates. As one means of minimizing off-target effects, directly transfected Cas9 protein reduces 260 the off-target cleavage rate when compared with Cas9 expression by a plasmid or mRNA 261 transfection in mammalian cells (16) . One recent study has demonstrated that direct delivery of 262 Cas9-gRNA ribonucleoprotein can facilitate genome editing in A. fumigatus (10). Based on these 263 improvements, we produced a simple, efficient, and accurate site-directed mutagenesis system to 264 investigate structure-phenotype relationships of the azole target Cyp51A. Since this system can 265 be applied to numerous genes other than cyp51A, this method will accelerate the progress of 266 many pathogenic fungal studies. 267 268 Multiple Gly138 polymorphisms in cyp51A have been identified in A. fumigatus azole-resistant 269 isolates, most of which alter Gly/GGC to Cys/TGC and Ser/AGC (22) (23) (24) (25) . Although 270
Saccharomyces cerevisiae expressing cyp51A with the Gly138Cys mutation showed reduced 271 susceptibility to all three azoles compared with the control strain, no genetic studies using A. 272 fumigatus as a host have been performed to date to investigate the function of Gly138 in 273
Cyp51A. We isolated an azole-resistant A. fumigatus strain from a CPPA patient with long-term 274 VRC treatment and identified two amino acid substitutions-Gly138Ser and 275
Asn248Lys-which, when compared with Cyp51A nucleotide sequences from azole-susceptible 276 strains, may be potential polymorphisms conferring azole resistance. According to the homology 277 model structure of the Cyp51A protein, Gly138 is located in a channel 1 helix close to the heme 278 cofactor, and a mutation at this position could disturb the heme environment, which may lead to 279 multiple azole resistance (26, 27) . Structure modeling and epidemiology have predicted that the 280 Gly138Ser mutation is the amino acid responsible for azole resistance, and our Cas9/CRISPR 281 gene replacement system has molecularly confirmed that the Ser138 is responsible for the 282 pan-azole-resistant phenotype in the clinical isolate NIID0345. However, genome-edited mutants 283
harboring Gly138 in the NIID0345 genetic background have exhibited much lower susceptibility 284 to all azoles tested than the strain AfS35, in which the amino acid at position 138 is intrinsically 285 glycine. Similarly, the genome-edited mutant harboring Ser138 in AfS35 genetic background has 286 exhibited higher susceptibility than the strain NIID0345, in which the amino acid at position 138 287 is intrinsically serine. These results indicate that the strain NIID0345 may have low azole 288 susceptibility for reasons other than alteration in cyp51A. Additional genomic analysis is needed 289 to identify unknown, non-Cyp51A mechanisms of azole resistance in the clinical isolate 290 NIID0345. 291
292
In conclusion, we have developed a simple, efficient, and accurate gene replacement system 293 using Cas9/CRISPR genome editing techniques, and applied these techniques to investigate the 294 mechanisms of azole resistance via Cyp51A alteration. We confirm at the molecular level that the 295 Gly138Ser mutation is one reason for azole resistance in a clinical isolate. There are many 296 cyp51A mutations that may result in potential, but unconfirmed amino acid changes conferring 297 azole resistance. Further investigation of Cyp51A using our Cas9/CRISPR system is required to 298 verify whether the diverse SNPs reported to date are in fact responsible for azole resistance. 299 300
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